 |
ARCHIVE # 4: 554 ARTICLES (NOV -SEPT 2006) |
|
|||||
My Educational Video on MS and MS Trials| Visitors Since 03/2006 |
||||||||||||||||||||||||||||||||||||||||
| Click here to read messages from our MySpace Friends HERE'S A FEW OF OUR 1,404 MySpace FRIENDS |
||||||||||||||||||||||||||||||||||||||||
 |
||||||||||||||||||||||||||||||||||||||||
| ||||||||||||||||||||||||||||||||||||||||
| ||||||||||||||||||||||||||||||||||||||||
| ||||||||||||||||||||||||||||||||||||||||
| ||||||||||||||||||||||||||||||||||||||||
| ||||||||||||||||||||||||||||||||||||||||
 Click to view 1280 MS Walk photos! | ||||||||||||||||||||||||||||||||||||||||
| "Join a trial at Barrow & receive all medication & study based procedures at no charge!" | ||||||||||||||||||||||||||||||||||||||||
Stan Swartz, CEO, The MD Health Channel "WE PRODUCED THE FOLLOWING 9 VIDEOS FOR YOU!" Simply click the "video" buttons below: . |
||||||||||||||||||||||||||||||||||||||||
|
||||||||||||||||||||||||||||||||||||||||
|
||||||||||||||||||||||||||||||||||||||||
|
||||||||||||||||||||||||||||||||||||||||
|
||||||||||||||||||||||||||||||||||||||||
|
||||||||||||||||||||||||||||||||||||||||
|
||||||||||||||||||||||||||||||||||||||||
| Previious Posts | ||||||||||||||||||||||||||||||||||||||||
|
||||||||||||||||||||||||||||||||||||||||
| MS NEWS ARCHIVES: by week | ||||||||||||||||||||||||||||||||||||||||
| September 2006 | ||||||||||||||||||||||||||||||||||||||||
| October 2006 | ||||||||||||||||||||||||||||||||||||||||
| November 2006 | ||||||||||||||||||||||||||||||||||||||||
| July 2013 | ||||||||||||||||||||||||||||||||||||||||
| April 2014 | ||||||||||||||||||||||||||||||||||||||||
Tuesday, October 17, 2006
Phase III Fampridine SR
Lazard raised their tgt on ACOR to $22 from $14 saying they hosted a dinner to discuss the Phase III Fampridine SR data and the reintroduction of Tysabri. The speakers agreed that Fampridine-SR would be appropriate for many of their M.S patients, possibly up to 50%. The speakers said the appeal is that the drug appears to improve symptoms independent of other MS treatments. The firm increased their 2009-10 annual pricing assumption to $7000 from $6000 per year, due to physicians' views that Fampridine-SR fills an unmet medical need and is more than a supportive-care drug. The firm says catalysts include initiating second Fampridine-SR Phase III trial in 1Q07, partnership for Fampridine-SR in Europe in 4Q06/1Q07.MORE
Lazard raised their tgt on ACOR to $22 from $14 saying they hosted a dinner to discuss the Phase III Fampridine SR data and the reintroduction of Tysabri. The speakers agreed that Fampridine-SR would be appropriate for many of their M.S patients, possibly up to 50%. The speakers said the appeal is that the drug appears to improve symptoms independent of other MS treatments. The firm increased their 2009-10 annual pricing assumption to $7000 from $6000 per year, due to physicians' views that Fampridine-SR fills an unmet medical need and is more than a supportive-care drug. The firm says catalysts include initiating second Fampridine-SR Phase III trial in 1Q07, partnership for Fampridine-SR in Europe in 4Q06/1Q07.MORE